Company: HSDTW
Filing Date: 2025-07-07
Form Type: 8-K
Source: 0001104659-25-066161
Chunk: 0

Company: Solana Co
Filing Date: 2025-07-07
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01.      Other Events.  

As previously disclosed, on June
23, 2023, Helius Medical Technologies, Inc., (the “ Company”), entered into a Sales Agreement (the “ Sales Agreement”)
with Roth Capital Partners, LLC (the “ Agent”), as sales agent, pursuant to which the Company may offer and sell shares of
the Company’s common stock, par value $0.001 per share (the “ Shares”). On July 7, 2025, the Company filed an updated
Prospectus Supplement (the “ Prospectus”) for the offer and sale of up to $25 million of Shares through the Agent pursuant
to the Sales Agreement.

The Shares have been registered
under the Securities Act of 1933, as amended (the “ Securities Act”), pursuant to the Company’s Registration Statement
on Form S-3 (File No. 333- 270433) (the “ Registration Statement”) and the Prospectus. Sales of the Shares,
if any, may be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of
the Securities Act, including sales made directly on or through The Nasdaq Global Market or any other existing trading market for the
Shares, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices
and/or any other method permitted by law. The Company intends to use the net proceeds, if any, from the offering for working capital and
general corporate purposes, which may include, among other things, funding commercialization efforts and research and development activities.

Honigman LLP, counsel to the Company,
has issued an opinion relating to the Shares. A copy of such legal opinion, including the consent included therein, is attached as Exhibit
5.1 hereto.

The Shares will be sold pursuant
to the Registration Statement, and offerings of the Shares will be made only by means of the Prospectus. This Current Report on Form 8-K
shall not constitute an offer to sell or solicitation of an offer to buy these securities, nor shall there be any sale of these securities
in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law
of such state or jurisdiction.